[Inhibitors of neoangiogenesis in antineoplastic therapy].
The role of angiogenesis in tumor growth and metastasis is discussed. The endogenous activators and inhibitors of tumor angiogenesis are presented and their mechanisms of action are reviewed. An overview on angiogenesis as a new potential target of antitumor therapy is described. The clinical trials of various antiangiogenic agents are briefly summarized and their differential mechanisms of action are discussed.
Opolski
A
A
Zakład Immunologii Nowotworów Instytutu Immunologii i Terapii Doświadczalnej PAN im. L. Hirszfelda we Wrocławiu.
Wietrzyk
J
J
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D006133:Growth Substances / Q000378:metabolism; D006801:Humans; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D012074:Remission Induction; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D006133:Growth Substances; D014409:Tumor Necrosis Factor-alpha
Inhibitory neoangiogenezy w terapii przeciwnowotworowej.